JP6568536B2 - パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法 - Google Patents

パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法 Download PDF

Info

Publication number
JP6568536B2
JP6568536B2 JP2016550994A JP2016550994A JP6568536B2 JP 6568536 B2 JP6568536 B2 JP 6568536B2 JP 2016550994 A JP2016550994 A JP 2016550994A JP 2016550994 A JP2016550994 A JP 2016550994A JP 6568536 B2 JP6568536 B2 JP 6568536B2
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
phosphopantethein
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016550994A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016536360A (ja
JP2016536360A5 (enExample
Inventor
ブランコ イェンコ
ブランコ イェンコ
グレゴル コセツ
グレゴル コセツ
ホルヴォイェ ペトコヴィチ
ホルヴォイェ ペトコヴィチ
ベルケ アイダ ポドゴルシェク
ベルケ アイダ ポドゴルシェク
イェルカ パホル
イェルカ パホル
アレン キューザック
アレン キューザック
オーダ コルネリア マリア シーボン
オーダ コルネリア マリア シーボン
バラジ スリニヴァサン
バラジ スリニヴァサン
Original Assignee
アキエス バイオ ディー．オー．オー．
アキエス バイオ ディー．オー．オー．
ライクスウニフェルシテイト フローニンゲン
ライクスウニフェルシテイト フローニンゲン
アカデミス ジーケンハイス フローニンゲン
アカデミス ジーケンハイス フローニンゲン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アキエス バイオ ディー．オー．オー．, アキエス バイオ ディー．オー．オー．, ライクスウニフェルシテイト フローニンゲン, ライクスウニフェルシテイト フローニンゲン, アカデミス ジーケンハイス フローニンゲン, アカデミス ジーケンハイス フローニンゲン filed Critical アキエス バイオ ディー．オー．オー．
Publication of JP2016536360A publication Critical patent/JP2016536360A/ja
Publication of JP2016536360A5 publication Critical patent/JP2016536360A5/ja
Application granted granted Critical
Publication of JP6568536B2 publication Critical patent/JP6568536B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016550994A 2013-11-04 2014-10-29 パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法 Expired - Fee Related JP6568536B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20130191457 EP2868662A1 (en) 2013-11-04 2013-11-04 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
EP13191457.4 2013-11-04
PCT/EP2014/073258 WO2015063177A1 (en) 2013-11-04 2014-10-29 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds

Publications (3)

Publication Number Publication Date
JP2016536360A JP2016536360A (ja) 2016-11-24
JP2016536360A5 JP2016536360A5 (enExample) 2017-12-21
JP6568536B2 true JP6568536B2 (ja) 2019-08-28

Family

ID=49518786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550994A Expired - Fee Related JP6568536B2 (ja) 2013-11-04 2014-10-29 パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法

Country Status (9)

Country Link
US (2) US9963472B2 (enExample)
EP (2) EP2868662A1 (enExample)
JP (1) JP6568536B2 (enExample)
CN (1) CN105764909B (enExample)
AU (1) AU2014343730B2 (enExample)
CA (1) CA2929369C (enExample)
DK (1) DK3066106T3 (enExample)
ES (1) ES2743921T3 (enExample)
WO (1) WO2015063177A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI24899A (sl) * 2014-12-23 2016-06-30 Acies Bio D.O.O. Fosfopanteteinske spojine,same ali v kombinaciji z inhibitorji HMG-COA reduktaze za zniževanje serumskega holesterola in serumskih trigliceridov
EP3386995A1 (en) * 2015-12-08 2018-10-17 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
EP3471828A1 (en) 2016-06-16 2019-04-24 Acies Bio d.o.o. Compositions and methods useful for treating diseases characterized by insufficient pantothenate kinase activity
JP2019523259A (ja) * 2016-07-25 2019-08-22 レトロフィン， インコーポレイテッド 神経性障害の処置のためのパンテテイン誘導体
CN106365998A (zh) * 2016-08-19 2017-02-01 陕西思尔生物科技有限公司 一种特戊酸碘甲酯的制备方法
CN107422056B (zh) * 2017-08-17 2020-04-24 山东裕欣药业有限公司 一种特戊酸碘甲酯的气相色谱检测方法及其制备方法
AU2019389168A1 (en) * 2018-11-30 2021-06-24 Comet Therapeutics, Inc. Pantetheine derivatives and uses thereof
CN115919822A (zh) * 2022-10-12 2023-04-07 深圳大学 泛硫乙胺在治疗阿尔茨海默病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE532299A (enExample) * 1953-10-07
AU2002326412A1 (en) 2001-07-20 2003-03-03 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
WO2012017400A1 (en) 2010-08-03 2012-02-09 North-West University Synthesis of acyl-pantetheine derivatives and the use thereof in the synthesis of acyl-coenzyme a derivatives
SI3112372T1 (sl) * 2012-04-27 2019-04-30 Retrophin, Inc. Derivati pantotenata za zdravljenje nevroloških motenj

Also Published As

Publication number Publication date
DK3066106T3 (da) 2019-09-16
CN105764909A (zh) 2016-07-13
US20160297840A1 (en) 2016-10-13
JP2016536360A (ja) 2016-11-24
AU2014343730B2 (en) 2019-08-01
EP3066106B1 (en) 2019-08-14
US9963472B2 (en) 2018-05-08
ES2743921T3 (es) 2020-02-21
CN105764909B (zh) 2019-12-06
WO2015063177A1 (en) 2015-05-07
CA2929369C (en) 2023-10-17
CA2929369A1 (en) 2015-05-07
EP3066106A1 (en) 2016-09-14
US20180118767A1 (en) 2018-05-03
EP2868662A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
JP2016536360A (ja) パントテン酸キナーゼ関連神経変性症（ｐｋａｎ）の治療のための安定なパンテテイン誘導体およびそのような化合物の合成方法
JP5107579B2 (ja) 新規の種類のヒストン脱アセチル化酵素阻害剤としてのＺｎ２＋キレートモチーフ係留短鎖脂肪酸
AU2014343730A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds
JP6307149B2 (ja) 癌細胞を選択的に死滅させるためのｔｒａｉｌエンハンサー
AU2009329784B2 (en) Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
KR20120087878A (ko) 1,3-프로판디설포닉 애시드의 수송을 위한 방법, 화합물 및 조성물
US20110014699A1 (en) Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
JP2022513392A (ja) 活性分子送達のための胆汁酸及びそれらの誘導体の抱合体
BR112014006600B1 (pt) Composto, composição farmacêutica contendo o referido composto, uso de um composto e processo para a sintetização de compostos
US20090306201A1 (en) Selective inhibitors for transferases
CA2945404A1 (en) Bone-selective osteogenic oxysterol bisphosphonate analogs
JP6560284B2 (ja) 神経系の障害の処置のためのパントテン酸誘導体
CN107257803A (zh) 用于治疗细菌感染的多粘菌素类抗菌剂
CN106061937A (zh) 新大麻萜酚衍生物
KR20250035619A (ko) 공유 에피토프-칼레티쿨린 상호 작용의 소분자 억제제 및 사용 방법
CN112218878A (zh) Ntcp抑制剂
US20180214461A1 (en) Phosphopantetheine compounds alone or in combination with hmg-coa reductase inhibitors for lowering serum cholesterol and serum triglicerides
US20190270698A1 (en) Compounds and methods for the treatment of neurodegenerative diseases
US20100028417A1 (en) Use of substituted glycerin derivatives for producing a pharmaceutical preparation
EP1968650A2 (en) Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
JP2014509633A (ja) スフィンゴ脂質シグナリングのモジュレーターとしての新規の複素環式化合物及びその使用
HUP0000080A2 (hu) Metallopeptidáz inhibitor hatású foszfonsav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190626

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190710

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190802

R150 Certificate of patent or registration of utility model

Ref document number: 6568536

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees